B. Riley upgraded shares of Arotech (NASDAQ:ARTX) from a neutral rating to a buy rating in a report issued on Monday. They currently have $5.00 target price on the stock. The analysts noted that the move was a valuation call. Arotech Corporation (NASDAQ:ARTX) net profit margin is 3.10% and weekly performance is -15.63%. On last trading day company shares ended up $3.94. Analysts mean target price for the company is $5.25. Arotech Corporation (NASDAQ:ARTX) distance from 50-day simple moving average is -8.92%.
ROI Acquisition Corp (NASDAQ:EVRY) had its price objective cut by Telsey Advisory Group from $6.00 to $3.00 in a report released on Monday. ROI Acquisition Corp (NASDAQ:EVRY) shares fell -21.84% in last trading session and ended the day on $1.36. EVRY Gross Margin is 22.30% and its return on assets is -6.20%. ROI Acquisition Corp (NASDAQ:EVRY) quarterly performance is -75.23%.
Sky-mobi Ltd (ADR) (NASDAQ:MOBI) said Friday that its Board of Directors has approved a fiscal year-end change from March 31 to December 31, beginning in the calendar year ending December 31, 2014. Sky-mobi Ltd (ADR) (NASDAQ:MOBI) shares moved down -6.81% in last trading session and was closed at $6.57, while trading in range of $6.49-$7.03. Sky-mobi Ltd (ADR) (NASDAQ:MOBI) year to date performance is 76.61.
Einstein Noah Restaurant Group (NASDAQ:BAGL) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a report released on Thursday. They currently have a $14.90 price objective on the stock. Einstein Noah Restaurant Group, Inc. (NASDAQ:BAGL) ended the last trading day at $14.58. Company weekly volatility is calculated as 2.54% and price to cash ratio as 65.32. Einstein Noah Restaurant Group, Inc. (NASDAQ:BAGL) showed a negative weekly performance of -5.45%.
Clovis Oncology (NASDAQ:CLVS) announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company’s novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β). Data from the study were presented in an oral presentation by Professor Jean-Charles Soria at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting. Clovis Oncology Inc (NASDAQ:CLVS) weekly performance is -26.17%. On last trading day company shares ended up $38.23. Analysts mean target price for the company is $98.63. Clovis Oncology Inc (NASDAQ:CLVS) distance from 50-day simple moving average is -34.71%.